Preliminary results and ongoing trials for aGVHD prophylaxis
| Regimen . | Donor type . | aGVHD (grade 3-4), % . | Relapse, % . | OS, % . | GRFS, % . | Ongoing trials . |
|---|---|---|---|---|---|---|
| PTCy/TAC/Aba | Haploidentical | 5.1 | 8.3 | 90.6 | 71.8 | — |
| PTCy/Rux∗ | MRD/MUD (8/8) | 15 | 85 | — | — | |
| PTCy/TAC/MMF/Ita† | Haploidentical | 0 | 5.5 | 90 | 83 | NCT03755414 |
| Ita/TAC/Siro | MRD/MUD (8/8) | 5 | — | — | 51 | NCT04339101 |
| Rux/TAC/Siro∗ | MRD/MUD (8/8)‡ | 11 | 6 | 77 | — | — |
| Rux/TAC/MTX∗ | MRD/MUD (8/8)‡ | 4 | 17 | 77 | 65 | NCT03427866 |
| Orca-T | MRD/MUD (8/8)‡ | 5 | — | 91 | 76 | NCT04013685, NCT05316701 |
| Orca-Q | Haploidentical | 4.7 | 9.5 | — | 71 | NCT03802695 |
| AAT | — | — | — | — | — | NCT03805789 |
| PTCy/ATG§ | Haploidentical | 5 | 13 | 83 | 63 | NCT05153226 |
| Regimen . | Donor type . | aGVHD (grade 3-4), % . | Relapse, % . | OS, % . | GRFS, % . | Ongoing trials . |
|---|---|---|---|---|---|---|
| PTCy/TAC/Aba | Haploidentical | 5.1 | 8.3 | 90.6 | 71.8 | — |
| PTCy/Rux∗ | MRD/MUD (8/8) | 15 | 85 | — | — | |
| PTCy/TAC/MMF/Ita† | Haploidentical | 0 | 5.5 | 90 | 83 | NCT03755414 |
| Ita/TAC/Siro | MRD/MUD (8/8) | 5 | — | — | 51 | NCT04339101 |
| Rux/TAC/Siro∗ | MRD/MUD (8/8)‡ | 11 | 6 | 77 | — | — |
| Rux/TAC/MTX∗ | MRD/MUD (8/8)‡ | 4 | 17 | 77 | 65 | NCT03427866 |
| Orca-T | MRD/MUD (8/8)‡ | 5 | — | 91 | 76 | NCT04013685, NCT05316701 |
| Orca-Q | Haploidentical | 4.7 | 9.5 | — | 71 | NCT03802695 |
| AAT | — | — | — | — | — | NCT03805789 |
| PTCy/ATG§ | Haploidentical | 5 | 13 | 83 | 63 | NCT05153226 |